Arcus biosciences retains rights to casdatifan, a potential best-in-class hif-2a inhibitor, and announces pricing of $150 million common stock offering

Hayward, calif.--(business wire)--arcus biosciences, inc. (nyse:rcus), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for patients with cancer, today announced that gilead's time-limited exclusive option rights to casdatifan have expired. in addition, arcus has announced the pricing of a $150 million common stock offering, which is subject to customary closing conditions and includes participation from new and existing.
RCUS Ratings Summary
RCUS Quant Ranking